The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia

Published:2013-02-28 Issue:4 Volume:88 Page:289-293
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol

Author:

Visco Carlo¹,Finotto Silvia¹,Pomponi Fabrizio¹,Sartori Roberto²,Laveder Francesco³,Trentin Livio⁴,Paolini Rossella⁵,Di Bona Eros¹,Ruggeri Marco¹,Rodeghiero Francesco¹

Affiliation:

1. Department of Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy

2. Department of Immunohematology; San Giacomo Hospital; Castelfranco Veneto Italy

3. Department of Oncology; San Martino Hospital; Belluno Italy

4. Department of Medicine, Hematology and Clinical Immunology Branch; Padua University School of Medicine; Padova Italy

5. Department of Oncohaematology; S. Maria della Misericordia Hospital; Rovigo Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23391/fullpdf

Reference35 articles.

1. Rituximab dose-escalation trial in chronic lymphocytic leukemia;O'Brien;J Clin Oncol,2001

2. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: A basis for the use of myeloablative therapies;Seymour;Leuk Lymphoma,1995

3. Therapy of chronic lymphocytic leukaemia;Hallek;Best Pract Res Clin Haematol,2010

4. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation;Rossi;Blood,2011

5. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group;Stilgenbauer;J Clin Oncol,2009

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNA Therapeutics for Cancers;RNA Therapeutics - History, Design, Manufacturing, and Applications [Working Title];2022-09-16

2. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia;Frontiers in Immunology;2021-10-25

3. Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends;Current Topics in Medicinal Chemistry;2019-06-20

4. Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia;Haematologica;2019-05-16

5. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies;Hematology/Oncology and Stem Cell Therapy;2018-03